All In Biotech

Drug Trial Radar · NCT07928570

A Clinical Study of MHB034C for Injection in Participants With Advanced Solid Tumors

A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of MHB034C for Injection in Participants With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

400

Planned (sponsor's estimate)

Start

Dec 20, 2026

Primary completion

Jun 15, 2028

Study completion May 19, 2029

Sponsor

Sponsor type
Industry
First posted
Nov 10, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is an open-label, multicenter, first-in-human (FIH) Phase I/II clinical study to evaluate the safety, tolerability, pharmacokinetic (PK) profile, and preliminary efficacy of MHB034C in participants with advanced solid tumors.

Conditions

  • Advanced Malignant Solid Tumor

Interventions

  • MHB034C for InjectionDrug

    MHB034C for Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase I Dose Escalation Stage: Incidence of DLTTime frame: At the end of Cycle 1 (each cycle is 21 days for Q3W administration and 28 days for Q2W administration)
  2. Phase I Dose Escalation Stage: Incidence of Adverse events (AEs)Time frame: from Day1 to 30 days after last dose
  3. Phase I Dose Escalation Stage: Incidence of Serious adverse events (SAEs)Time frame: from Day1 to 30 days after last dose
  4. Phase I Dose Escalation Stage: MTDTime frame: At the end of Cycle 1 (each cycle is 21 days for Q3W administration and 28 days for Q2W administration)
  5. Phase I Dose Escalation Stage: RP2DTime frame: from Day1 to 30 days after last dose
  6. Phase II Dose Expansion Stage: ORR as assessed by the investigator per RECIST v1.1.Time frame: One year after the last subject was enrolled in the group
  7. Phase II Dose Expansion Stage: DCR as assessed by the investigator per RECIST v1.1.Time frame: One year after the last subject was enrolled in the group
  8. Phase II Dose Expansion Stage: DoR as assessed by the investigator per RECIST v1.1.Time frame: One year after the last subject was enrolled in the group
  9. Phase II Dose Expansion Stage: PFS as assessed by the investigator per RECIST v1.1.Time frame: One year after the last subject was enrolled in the group
  10. Phase II Dose Expansion Stage: OS as assessed by the investigator per RECIST v1.1.Time frame: One year after the last subject was enrolled in the group
  11. Phase II Dose Expansion Stage: PFS rates at 6 and 12 months.Time frame: One year after the last subject was enrolled in the group
  12. Phase II Dose Expansion Stage: OS rates at 6 and 12 months.Time frame: One year after the last subject was enrolled in the group

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.